Supplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Year: 2025
Type: supplementary-materials
Abstract: Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
Authors: Susana S. Najera, Christopher J. Ricketts, Laura S. Schmidt, Julia I. Medina, Keita Saito, Lilia Ileva, Jeffrey R. Brender, Amy M. James, Cody J. Peer, Brad Gouker, Baktiar O. Karim, Olga Chernova, Catherine Wells, Ming-Hui Wei, Youfeng Yang, Xiaohu Zhang, Carleen Klumpp-Thomas, Jameson Travers, Lu Chen, Kelli M. Wilson, Sameer H. Issaq, William D. Figg, Simone Difilippantonio, Joseph D. Kalen, Murali C. Krishna, Craig J. Thomas, Michele Ceribelli, Christine M. Heske, Daniel R. Crooks, Jordan L. Meier
Language: English
Subfield: Geriatrics and Gerontology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4407145913